Immunotherapy of allergic diseases

T. Nakagawa, M. Eric Gershwin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Immunotherapy (IT) of IgE-mediated diseases has been used since its first description in 1911. This therapy has been used in patients with inhalant allergy and insect venom sensitivity. Unfortunately, IT suffers from the crudeness of the allergy extracts and the inability to define allergenic epitopes. Moreover, this form of IT has been increasingly questioned because of improvements in pharmacotherapy and the risks of untoward reactions. These untoward reactions even include anaphylaxis and death. Despite this criticism, there are increasing data on the efficacy of immunotherapy and considerable research is underway to improve the risk-benefit ratio of treatment. Other approaches directed at inhibiting the sequential events of both the afferent and efferent limbs of allergic reactions are in progress. This involves specific alterations of target cells, i.e., mast cells and basophils. Moreover, the development of recombinant allergens and the precise definition of the binding site of IgE will further promote research and development of new means of IT. Gene targeting therapy may follow, directed at T cells specific for allergen epitope(s) or IgE binding sites. The future holds great promise and excitement.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalInternational Archives of Allergy and Immunology
Volume102
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Immunotherapy
Immunoglobulin E
Hypersensitivity
Allergens
Epitopes
Binding Sites
Gene Targeting
Basophils
Venoms
Anaphylaxis
Research
Mast Cells
Genetic Therapy
Insects
Extremities
Odds Ratio
T-Lymphocytes
Drug Therapy
Therapeutics

Keywords

  • Allergens
  • IgG subclass antibodies
  • Immune complexes
  • Immunotherapy
  • Oral desensitization
  • Peptide therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Immunotherapy of allergic diseases. / Nakagawa, T.; Gershwin, M. Eric.

In: International Archives of Allergy and Immunology, Vol. 102, No. 2, 1993, p. 117-120.

Research output: Contribution to journalArticle

@article{b571af7201784405974af2db2a329a8b,
title = "Immunotherapy of allergic diseases",
abstract = "Immunotherapy (IT) of IgE-mediated diseases has been used since its first description in 1911. This therapy has been used in patients with inhalant allergy and insect venom sensitivity. Unfortunately, IT suffers from the crudeness of the allergy extracts and the inability to define allergenic epitopes. Moreover, this form of IT has been increasingly questioned because of improvements in pharmacotherapy and the risks of untoward reactions. These untoward reactions even include anaphylaxis and death. Despite this criticism, there are increasing data on the efficacy of immunotherapy and considerable research is underway to improve the risk-benefit ratio of treatment. Other approaches directed at inhibiting the sequential events of both the afferent and efferent limbs of allergic reactions are in progress. This involves specific alterations of target cells, i.e., mast cells and basophils. Moreover, the development of recombinant allergens and the precise definition of the binding site of IgE will further promote research and development of new means of IT. Gene targeting therapy may follow, directed at T cells specific for allergen epitope(s) or IgE binding sites. The future holds great promise and excitement.",
keywords = "Allergens, IgG subclass antibodies, Immune complexes, Immunotherapy, Oral desensitization, Peptide therapy",
author = "T. Nakagawa and Gershwin, {M. Eric}",
year = "1993",
language = "English (US)",
volume = "102",
pages = "117--120",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Immunotherapy of allergic diseases

AU - Nakagawa, T.

AU - Gershwin, M. Eric

PY - 1993

Y1 - 1993

N2 - Immunotherapy (IT) of IgE-mediated diseases has been used since its first description in 1911. This therapy has been used in patients with inhalant allergy and insect venom sensitivity. Unfortunately, IT suffers from the crudeness of the allergy extracts and the inability to define allergenic epitopes. Moreover, this form of IT has been increasingly questioned because of improvements in pharmacotherapy and the risks of untoward reactions. These untoward reactions even include anaphylaxis and death. Despite this criticism, there are increasing data on the efficacy of immunotherapy and considerable research is underway to improve the risk-benefit ratio of treatment. Other approaches directed at inhibiting the sequential events of both the afferent and efferent limbs of allergic reactions are in progress. This involves specific alterations of target cells, i.e., mast cells and basophils. Moreover, the development of recombinant allergens and the precise definition of the binding site of IgE will further promote research and development of new means of IT. Gene targeting therapy may follow, directed at T cells specific for allergen epitope(s) or IgE binding sites. The future holds great promise and excitement.

AB - Immunotherapy (IT) of IgE-mediated diseases has been used since its first description in 1911. This therapy has been used in patients with inhalant allergy and insect venom sensitivity. Unfortunately, IT suffers from the crudeness of the allergy extracts and the inability to define allergenic epitopes. Moreover, this form of IT has been increasingly questioned because of improvements in pharmacotherapy and the risks of untoward reactions. These untoward reactions even include anaphylaxis and death. Despite this criticism, there are increasing data on the efficacy of immunotherapy and considerable research is underway to improve the risk-benefit ratio of treatment. Other approaches directed at inhibiting the sequential events of both the afferent and efferent limbs of allergic reactions are in progress. This involves specific alterations of target cells, i.e., mast cells and basophils. Moreover, the development of recombinant allergens and the precise definition of the binding site of IgE will further promote research and development of new means of IT. Gene targeting therapy may follow, directed at T cells specific for allergen epitope(s) or IgE binding sites. The future holds great promise and excitement.

KW - Allergens

KW - IgG subclass antibodies

KW - Immune complexes

KW - Immunotherapy

KW - Oral desensitization

KW - Peptide therapy

UR - http://www.scopus.com/inward/record.url?scp=0027361314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027361314&partnerID=8YFLogxK

M3 - Article

C2 - 8400891

AN - SCOPUS:0027361314

VL - 102

SP - 117

EP - 120

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 2

ER -